Bender Whitney R, Mccoy Jennifer A, Levine Lisa D
Pregnancy and Perinatal Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA (Drs Bender, Mccoy and Levine); Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, PA (Dr Bender).
Pregnancy and Perinatal Research Center, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA (Drs Bender, Mccoy and Levine).
Am J Obstet Gynecol MFM. 2024 Aug;6(8):101414. doi: 10.1016/j.ajogmf.2024.101414. Epub 2024 Jun 25.
Induction of labor (IOL) is recommended following prelabor rupture of membranes (PROM). The optimal method for IOL and need for cervical ripening in those with PROM and an unfavorable cervical examination is unclear.
To determine if oxytocin or oral misoprostol results in a shorter time to delivery among nulliparous patients with an unfavorable cervical examination and PROM diagnosis and to evaluate patient satisfaction with both methods.
This is a randomized clinical trial conducted at an urban tertiary care center from 2019 to 2023. Subjects were nulliparas ≥36 weeks with an unfavorable starting cervical exam (≤2 cm and Bishop <8). The primary outcome was time from IOL to delivery in hours compared between oxytocin vs oral misoprostol. Secondary outcomes included suspected intraamniotic infection, cesarean delivery, composite maternal and neonatal morbidity, and patient satisfaction (assessed by Birth Satisfaction Scale-Revised). Sub-group analyses for those with BMI ≥ 30 kg/m and cervical dilation ≥1 cm were performed. We required 148 subjects to have 80% power to detect a 2-hour difference in time to delivery. The study was stopped early by the data safety monitoring board due to feasibility concerns in recruiting desired sample size.
A total of 108 subjects were randomized: 56 oxytocin; 52 oral miso. The median gestational age at induction was 39.5 weeks; the mean starting cervical dilation was 1.1 cm. There was no statistical difference in time to delivery between groups overall: 14.9 hours oxytocin vs 18.1 hours oral misoprostol (P=.06). In sub-group analyses, there was a 5 hours shorter time to delivery with oxytocin for those with a BMI ≥ 30 kg/m (16.6 hours oxytocin vs 21.8 hours oral misoprostol, P .04) and 4.5 hours shorter time to delivery with oxytocin for those with cervix ≥1 cm (12.9 hours oxytocin vs 17.3 hours oral misoprostol, P .04). There were no differences in intraamniotic infection, cesarean delivery, maternal or neonatal morbidity between the groups. Patient satisfaction was higher for those receiving oxytocin compared to misoprostol (29.0 vs 26.3, P=.03).
Among nulliparas with PROM and an unfavorable cervix, there was no difference in overall time to delivery between oxytocin and oral misoprostol. This result should be interpreted with caution given early study discontinuation and inadequate power. However, a shorter time to delivery with oxytocin was noted in obese patients and those with cervical dilation of at least 1 cm. Furthermore, patient satisfaction was higher in the oxytocin group, and there was no increased risk of neonatal or maternal morbidity with oxytocin.
胎膜早破(PROM)后建议引产(IOL)。对于PROM且宫颈检查结果不佳的患者,引产的最佳方法以及宫颈成熟的必要性尚不清楚。
确定缩宫素或口服米索前列醇在宫颈检查结果不佳且诊断为PROM的初产妇中是否能缩短分娩时间,并评估患者对这两种方法的满意度。
这是一项于2019年至2023年在城市三级医疗中心进行的随机临床试验。受试者为孕周≥36周的初产妇,起始宫颈检查结果不佳(≤2 cm且Bishop评分<8)。主要结局是缩宫素与口服米索前列醇相比从引产到分娩的时间(以小时计)。次要结局包括疑似羊膜腔内感染、剖宫产、孕产妇和新生儿综合发病率以及患者满意度(通过修订版分娩满意度量表评估)。对体重指数(BMI)≥30 kg/m²且宫颈扩张≥1 cm的患者进行了亚组分析。我们需要148名受试者才能有80%的把握检测到分娩时间有2小时的差异。由于招募所需样本量存在可行性问题,该研究被数据安全监测委员会提前终止。
共有108名受试者被随机分组:56名使用缩宫素;52名口服米索前列醇。引产时的中位孕周为39.5周;起始宫颈平均扩张为1.1 cm。总体而言,两组之间的分娩时间无统计学差异:缩宫素组为14.9小时,口服米索前列醇组为18.1小时(P = 0.06)。在亚组分析中,BMI≥30 kg/m²的患者使用缩宫素分娩时间缩短5小时(缩宫素组为16.6小时,口服米索前列醇组为21.8小时,P = 0.04),宫颈扩张≥1 cm的患者使用缩宫素分娩时间缩短4.5小时(缩宫素组为12.9小时,口服米索前列醇组为17.3小时,P = 0.04)。两组之间在羊膜腔内感染、剖宫产、孕产妇或新生儿发病率方面无差异。与米索前列醇相比,接受缩宫素的患者满意度更高(29.0对26.3,P = 0.03)。
在PROM且宫颈条件不佳的初产妇中,缩宫素和口服米索前列醇的总体分娩时间无差异。鉴于研究提前终止且效能不足,该结果应谨慎解读。然而,肥胖患者和宫颈扩张至少1 cm的患者使用缩宫素时分娩时间较短。此外,缩宫素组患者满意度更高,且使用缩宫素不会增加新生儿或孕产妇发病风险。